SCHEMBL90733

SCHEMBL90733

CCOCCCc1ccccc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 1/20 0.58
SMN1; SMN2 Q16637 1/20 0.58
IDO1 P14902 1/20 0.57
MEN1 O00255 1/20 0.51
KMT2A Q03164 1/20 0.51
HRH3 Q9Y5N1 3/20 0.50
TDP1 Q9NUW8 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
LMNA P02545 1/20 0.48
CHRM2 P08172 1/20 0.48
HTR1A P08908 1/20 0.48
ADRA2A P08913 1/20 0.48
CHRM1 P11229 1/20 0.48
DRD1 P21728 1/20 0.48
SLC6A2 P23975 1/20 0.48
SLC6A4 P31645 1/20 0.48
ADRA1A P35348 1/20 0.48
OPRM1 P35372 1/20 0.48
DRD3 P35462 1/20 0.48
SLC6A3 Q01959 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20170449 0.96 RAB9A (0.55) RAB9ASMN1; SMN2IDO1MEN1KMT2A
SCHEMBL14030598 0.94 RAB9A (0.57) RAB9ASMN1; SMN2IDO1MEN1KMT2A
SCHEMBL28037453 0.92 L3MBTL1 (0.58) RAB9ASMN1; SMN2IDO1TDP1L3MBTL1
SCHEMBL12040626 0.92 L3MBTL1 (0.58) RAB9ASMN1; SMN2IDO1TDP1L3MBTL1
SCHEMBL22281733 0.92 L3MBTL1 (0.58) RAB9ASMN1; SMN2IDO1TDP1L3MBTL1
SCHEMBL23014825 0.92 L3MBTL1 (0.58) RAB9ASMN1; SMN2IDO1TDP1L3MBTL1
SCHEMBL75088 0.86 RAB9A (0.53) RAB9ASMN1; SMN2IDO1MEN1KMT2A
SCHEMBL196951 0.86 IDO1 (0.67) IDO1MEN1KMT2AHRH3TDP1
SCHEMBL4871162 0.85 IDO1 (0.55) IDO1MEN1KMT2AHRH3TDP1
SCHEMBL3438768 0.85 HRH3 (0.57) IDO1MEN1KMT2AHRH3TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020018087-A1 POLYURETHANE FOAM ADDITIVES TO IMPROVE FOAM ADHESION TO ORGANIC POLYMERS EVONIK DEGUSSA GMBH (DE) 2020-01-23 WO claimed
EP-3233737-B1 SCALE INHIBITOR COMPOSITIONS AND METHODS OF USING CYTEC IND INC (US) 2019-05-08 EP claimed
CN-105949729-B Thermoplastic molding compounds 朗盛德国有限责任公司 2018-04-17 CN claimed
CN-107892798-A Thermoplastic molded compound 朗盛德国有限责任公司 2018-04-10 CN claimed
CN-106588817-A Method for synthesizing eperisone hydrochloride 湖南亚大制药有限公司 2017-04-26 CN claimed
US-20060142277-A1 Substituted aralkyl derivatives CADILA HEALTHCARE LIMITED 2006-06-29 US claimed
EP-0187956-A2 Pharmaceutical composition for the treatment of defects of the gastrointestinal mucous membrane BOEHRINGER INGELHEIM KG (DE) 1986-07-23 EP claimed
US-11857519-B2 Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide ARVINAS OPERATIONS, INC. (US) 2024-01-02 US disclosed
EP-4279476-A1 METHOD FOR ALKYLATING ACIDIC FUNCTIONAL GROUP CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2023-11-22 EP disclosed
WO-2023181365-A1 METAL VAPOR DEPOSITED FILM 株式会社麗光 2023-09-28 WO disclosed
WO-2023136273-A1 ADHESIVE COMPOSITION, ADHESIVE FILM FOR CIRCUIT CONNECTION, AND METHOD FOR PRODUCING CONNECTION STRUCTURE 株式会社レゾナック 2023-07-20 WO disclosed
WO-2023136274-A1 ADHESIVE AGENT COMPOSITION, ADHESIVE AGENT FILM FOR CIRCUIT CONNECTION, AND MANUFACTURING METHOD FOR CONNECTION STRUCTURE 株式会社レゾナック 2023-07-20 WO disclosed
WO-2023136286-A1 ADHESIVE COMPOSITION, ADHESIVE FILM FOR CIRCUIT CONNECTION, AND METHOD FOR PRODUCING CONNECTION STRUCTURE 株式会社レゾナック 2023-07-20 WO disclosed
WO-1996014283-A1 PROCESS AND INTERMEDIATES FOR PREPARING TRIPHENYLTRIFLUOROPROPANES AND -PROPENES EGIS Gyógyszergyár Rt. (HU) 1996-05-17 WO disclosed
WO-1996001876-A1 SYNTHETIC MORTAR RESIN COMPOSITIONS CRAY VALLEY S.A. (FR) 1996-01-25 WO disclosed
US-5164434-A Sulfide compound for thermal and/or oxidative stabilization of polymers ROHM AND HAAS COMPANY (US) 1992-11-17 US disclosed
US-4704006-A HIGH REFRACTIVE INDEX, DYEABILITY, SOLVENT RESISTANCE KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) 1987-11-03 US disclosed
EP-0142921-B1 HALOGEN-CONTAINING RESIN LENS MATERIAL KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) 1987-08-26 EP disclosed
EP-0187956-A2 Pharmaceutical composition for the treatment of defects of the gastrointestinal mucous membrane BOEHRINGER INGELHEIM KG (DE) 1986-07-23 EP disclosed
EP-0142921-A1 Halogen-containing resin lens material KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) 1985-05-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060142277-A1 Substituted aralkyl derivatives UGT1A7, UGT1A10, UGT2B7 RAB9A 543/4885SMN1; SMN2 2873/4885IDO1 3097/4885
US-11857519-B2 Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide CRBN, MDM2, VHL RAB9A 3643/4885SMN1; SMN2 881/4885IDO1 3408/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.